TiGenix: Publication of prospectus and response memorandum for Takeda takeover bid commencing on April 30, 2018

    NEXT STORY
    ThromboGenics Initiates Phase 2 Clinical Study Evaluating anti-PlGF (THR-317) in combination with anti-VEGF (ranibizumab) for treatment of Diabetic Macular Edema (DME)
    PREV STORY
    CrownBio Melancarkan Model Sasaran Disesuaikan Baharu untuk Imunoterapi
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Zai Lab Announces Early Completion of Enrollment for ZL-2306 PK Study

    SHANGHAI, China, May 21, 2018 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ:ZLAB), a Shanghai-based ...

    author_avatar
    NASDAQ Market News

    Immune Design to Report First Quarter 2018 Financial Results and Provide Corporate Update

    author_avatar
    NASDAQ Market News

    NeuBase Therapeutics Designates Industry Leaders to Board of Directors 

    author_avatar
    NASDAQ Market News